Browse by author
Lookup NU author(s): Professor Ian McKeith
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Two suggested clinical trial designs for assessing progression of Alzheimer disease are the randomized withdrawal design and the randomized start design. The most promising of these, the randomized start design, has the potential to demonstrate a delay in progression, but there remain problematic design, ethical, and statistical issues to be solved before the protocol can be used in a clinical trial. The development of biological markers of the disease process using neuroimaging or other measures also may provide a robust method of measuring disease progression and demonstrating the biological effect of a drug on the disease process.
Author(s): McKeith IG; Bodick N; Forette F; Hadler D; Harvey RJ; Leber P; Riekkinen PJ; Rossor MN; Scheltens P; Shimohama S; Spiegel R; Tanaka S; Thal LJ; Urata Y; Whitehouse P; Wilcock G
Publication type: Article
Publication status: Published
Journal: Alzheimer Disease and Associated Disorders
Print publication date: 01/01/1997
ISSN (print): 0893-0341
ISSN (electronic): 1546-4156
Publisher: Lippincott Williams & Wilkins